title: QTc interval in infants receiving cisapride.
abstract: OBJECTIVE
  To examine the effect of cisapride on the corrected QT (QTc) interval in infants over a 14-day period.
  
  
  METHODS
  A prospective cohort study of infants receiving cisapride (0.8 mg/kg per day). Twelve-lead electrocardiograms were obtained before and 3, 5, 7, and 14 days after cisapride initiation.
  
  
  RESULTS
  Fifty infants completed the study; none had arrhythmias. Fifteen of 50 infants (30%) developed QTc interval > or =450 msec; QTc interval normalized in 13 of 15 infants. Infants with QTc interval on day 3 > or =2 standard deviations above the mean baseline QTc interval (401+40 msec) were more likely to develop prolonged QTc interval (p<0.0001).
  
  
  CONCLUSIONS
  QTc interval prolongation was noted in 30% of infants. Subsequently, the majority of those infants had QTc interval normalization by day 14 of cisapride therapy. QTc interval 3 days following cisapride initiation may identify infants at risk for transient QTc interval prolongation. With appropriate monitoring, hospitalized infants receiving cisapride may have improved gastrointestinal motility without cardiac morbidity.
authors.affiliation: Doctor's Hospital, Laredo, TX, USA.
authors.forename: Satbir
authors.initials: S
authors.lastname: Chhina
authors.forename: Ricardo L
authors.initials: RL
authors.lastname: Peverini
authors.forename: Douglas D
authors.initials: DD
authors.lastname: Deming
authors.forename: Andrew O
authors.initials: AO
authors.lastname: Hopper
authors.forename: Aijaz
authors.initials: A
authors.lastname: Hashmi
authors.forename: Nidia R
authors.initials: NR
authors.lastname: Vyhmeister
mesh_terms: D000704:Analysis of Variance; D020117:Cisapride / Q000008:administration & dosage* / Q000009:adverse effects; D015331:Cohort Studies; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004562:Electrocardiography; D015154:Esophageal Motility Disorders / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D005769:Gastrointestinal Motility / Q000187:drug effects; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007363:Intensive Care Units, Neonatal; D008297:Male; D011336:Probability; D011446:Prospective Studies; D018570:Risk Assessment; D016896:Treatment Outcome
chemical_list: D020117:Cisapride